Semaglutide (Wegovy), approved at a 2.4 mg weekly dose, represents the most potent GLP-1 receptor agonist currently available for weight management
What is legal now, and what is under review Only a limited number of peptide therapies are currently available through licensed prescribing pathways
who demonstrated the power of fitting DLS and SLS data jointly to determine protein-protein interactions, as a global fit of both DLS and SLS data is necessary to obtain meaningful interaction parameters, since DLS alone can lead to different interpretations (Parupudi et al., 2021)
In a recent study of racial and ethnic differences in the trajectories of Medicare expenditures, researchers found that nonHispanic Black individuals with dementia had the highest Medicare expenditures overall and highest expenditures in the last year of life ($51,294 in 2016 dollars for nonHispanic Black, $47,469 for Hispanic, and $39,499 for White Medicare beneficiaries [$64,088, $59,309, and $49,351 in 2025 dollars, respectively])
For a deeper look at how they stack up, check our Biotech Peptides vs Peptide Sciences comparison
